The global CD Antigen Cancer Therapy Market is valued at USD 27.5 Billion in 2024 and is projected to reach a value of USD 54 ...

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...

In the absence of PAMPs, damage-associated molecular patterns (DAMPs) produced by dying cells can stimulate an immune response that can elicit the specific recognition of antigens expressed by ...

We sought to determine whether immune reactivity occurs between anti-SARS-CoV-2 protein antibodies and human tissue antigens, and whether molecular mimicry between COVID-19 viral proteins and human ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

Although CAR T-cell therapies have reached significant clinical success in hematological malignancies, their utility in solid tumors remains limited. One of the main challenges is the scarcity of ...

Chimeric antigen receptor (CAR) T-cell therapy has revolutionised the treatment of haematological malignancies and has demonstrated efficacy in early trials for solid tumours, neurological and ...

With every bite of food we take, our intestinal immune system must make a big decision. Tasked with defending us from foreign pathogens, these exquisitely sensitive cells somehow distinguish friend ...

MSCs regulate many effector functions of innate immune cells, such as antigen presentation by dendritic cells (DCs), natural killer (NK)-cell cytotoxicity and the activation of neutrophils.

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, ...

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors—a smart fighter that destroys ...